Vir Biotechnology (MEX:VIR) Total Stockholders Equity: MXN17,144 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VIR Vir Biotechnology Inc MEX:VIR
52 GF Score
Price MXN170.00
GF Value MXN764.28
! 5 Warning Signs
View Full Analysis

What is Vir Biotechnology Total Stockholders Equity?

Vir Biotechnology MEX:VIR 52 Total Stockholders Equity is MXN17,144 Mil as of Jun. 2026. GuruFocus rates MEX:VIR with a GF Score™ of 52/100 and a GF Value™ of MXN764.28. The stock has 5 warning signs investors should review.

Vir Biotechnology's Total Stockholders Equity for the quarter that ended in Jun. 2026 was MXN17,144 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vir Biotechnology's Book Value per Share for the quarter that ended in Jun. 2026 was MXN101.33. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vir Biotechnology's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.09.

Vir Biotechnology  (MEX:VIR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vir Biotechnology's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(17143.52-0)/169.186
=101.33

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vir Biotechnology's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(159.432 + 1468.107) / 17143.52
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vir Biotechnology Total Stockholders Equity Related Terms

Vir Biotechnology Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vir Biotechnology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vir Biotechnology Total Stockholders Equity Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 29,372.95 40,511.97 26,993.06 23,992.08 13,779.33

Vir Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17,840.14 14,603.78 13,779.33 14,656.35 17,143.52
MEX:VIR
52GF Score
Vir Biotechnology Inc MEX:VIR
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN17,144 Mil mean?
Vir Biotechnology (MEX:VIR) has a Total Stockholders Equity of MXN17,144 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vir Biotechnology and its competitors.
Is Vir Biotechnology's Total Stockholders Equity too high?
Vir Biotechnology's current Total Stockholders Equity is MXN17,144 Mil. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Total Stockholders Equity compare to AVBP and XNCR?
Vir Biotechnology's Total Stockholders Equity of MXN17,144 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vir Biotechnology and its competitors. Vir Biotechnology's current Total Stockholders Equity is MXN17,144 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current Total Stockholders Equity of MXN17,144 Mil. The stock's GF Value™ is MXN764.28, compared to a current price of MXN170.00 — trading 77.8% below its estimated fair value. The current Total Stockholders Equity is MXN17,144 Mil. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current Total Stockholders Equity is MXN17,144 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?

Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued. The current stock price of MXN170.00 is trading 77.8% below its estimated GF Value™ of MXN764.28.

Key valuation signals for MEX:VIR:

  • Total Stockholders Equity: MXN17,144 Mil
  • GF Value™: MXN764.28 vs. price of MXN170.00 (77.8% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vir Biotechnology Business Description

Other Exchanges VIR:USA
Address 1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score

Get the complete analysis for MEX:VIR

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN170.00
Price
MXN764.28
GF Value